Global fill/finish Cangene bioPharma operates an established fill/finish manufacturing plant with regulatory approvals across US, EU, Brazil, Middle East and Japan, offering reliable CDMO capabilities for sterile liquid and lyophilized products. This positions the company to target pharmaceutical and biotech sponsors seeking compliant, multinational manufacturing support.

Wide product scope The facility currently produces 24 commercial products and has contributed to the development and production of over 185 clinical products since 1990, indicating depth in process development, scale-up, and lifecycle management that can attract clients needing turnkey manufacturing readiness.

Global distribution Manufactured products are distributed to more than 50 countries, suggesting established international logistics, regulatory familiarity, and potential for new clients requiring global supply chain reach and regional regulatory support.

Acquisition leverage Emergent BioSolutions’ acquisition of Cangene bioPharma creates a potential cross-sell opportunity to integrate contract manufacturing with Emergent’s healthcare solutions portfolio, offering clients expanded access to additional technologies, programs, and government-focused capabilities.

SMB to mid-market focus With a revenue band of one to several million and a mid-sized employee base, there is opportunity to engage small to mid-tier biotech and emerging companies seeking scalable, compliant fill/finish capacity and flexible terms that align with early growth or late-stage development needs.